[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336498-105":59,"doc-detail-336498-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","determining-m2-macrophages-content-for-the-anti-tumor-effects-of-metal-organic-framework-encapsulated-pazopanib-nanoparticles-in-breast-cancer","Determining M2 macrophages content for the anti-tumor effects of metal-organic framework-encapsulated pazopanib nanoparticles in breast cancer","","Pazopanib (PAZ), an oral multi-tyrosine kinase inhibitor, shows anti-cancer cytostatic effects but is constrained by side effects and treatment resistance. A nanoplatform was developed to deliver PAZ and enhance anti-breast cancer therapy using nanometer-sized PAZ@Fe-MOF. Compared with free PAZ, PAZ@Fe-MOF increased therapeutic anti-tumor activity in 4T1 and MDA-MB-231 models. Single-cell RNA sequencing indicated reduced pro-tumorigenic M2-like macrophages and suppressed M2 signaling pathways including ATF6-TGFBR1-SMAD3, as well as chemokines CCL17, CCL22, and CCL24. The approach reprogrammed the inhibitory immune microenvironment by blocking M2 polarization and improved PAZ cytotoxicity while enabling evaluation of immunological responses.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/determining-m2-macrophages-content-for-the-anti-tumor-effects-of-metal-organic-framework-encapsulated-pazopanib-nanoparticles-in-breast-cancer/336498/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/determining-m2-macrophages-content-for-the-anti-tumor-effects-of-metal-organic-framework-encapsulated-pazopanib-nanoparticles-in-breast-cancer/336498.png","ImageObject",300,407,{"name":92,"@type":93},"Noah","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main strategy developed in this study?","Question",{"text":112,"@type":113},"The study develops a nanoplatform that delivers pazopanib (PAZ) using nanometer-sized PAZ@Fe-MOF to improve anti-breast cancer effects.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does PAZ@Fe-MOF perform compared with free PAZ?",{"text":117,"@type":113},"PAZ@Fe-MOF shows increased anti-tumor therapeutic activity in both syngeneic murine 4T1 and xenograft human MDA-MB-231 breast cancer models.",{"name":119,"@type":110,"acceptedAnswer":120},"How does PAZ@Fe-MOF affect M2-like macrophages in the tumor site?",{"text":121,"@type":113},"High-throughput single-cell RNA sequencing indicates that PAZ@Fe-MOF significantly reduces pro-tumorigenic M2-like macrophage populations and suppresses M2-type signaling pathways and chemokines including CCL17, CCL22, and CCL24.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336498,1790155986,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","Xu etal. Journal of Nanobiotechnology (2024) 22:429  \n[https://doi.org/10.1186/s12951-024-02694-z](https://doi.org/10.1186/s12951-024-02694-z)  \nJournal of Nanobiotechnology  \nRESEARCH Open Access  \nDetermining M2 macrophages content for the anti-tumor effects of metal-organic framework-encapsulated pazopanib nanoparticles in breast cancer  \nZhijie Xu 1,2†, Zhiyang Zhou3,4†, Xiaoxin Yang5, Abhimanyu Thakur6, Ning Han2, Hai-Tao Li2, Liu-Gen Li2, Jun Hu2*, Tong-fei Li2* and Yuanliang Yan7,8*  \nAbstract  \nPazopanib (PAZ), an oral multi-tyrosine kinase inhibitor, demonstrates promising cytostatic activities against various human cancers. However, its clinical utility is limited by substantial side effects and therapeutic resistance. We developed a nanoplatform capable of delivering PAZ for enhanced anti-breast cancer therapy. Nanometer-sized PAZ@Fe-MOF, compared to free PAZ, demonstrated increased anti-tumor therapeutic activities in both syngeneic murine 4T1 and xenograft human MDA-MB-231 breast cancer models. High-throughput single-cell RNA sequencing (scRNAseq) revealed that PAZ@Fe-MOF significantly reduced pro-tumorigenic M2-like macrophage populations at tumor sites and suppressed M2-type signaling pathways, such as ATF6-TGFBR1-SMAD3, as well as chemokines including CCL17, CCL22, and CCL24 . PAZ@Fe-MOF reprogramed the inhibitory immune microenvironment and curbed tumorigenicity by blocking the polarization of M2 phenotype macrophages. This platform offers a promising and new strategy for improving the cytotoxicity of PAZ against breast cancers. It provides a method to evaluate the immunological response of tumor cells to PAZ-mediated treatment.  \nKeywords Pazopanib, Metal-organic framework, Immune microenvironment, M2-like macrophages, Breast cancer  \n†Zhijie Xu and Zhiyang Zhou contribute equally to the present work.  \n*Correspondence: Jun Hu [junhu2023@163.com](junhu2023@163.com)[ ](junhu2023@163.com)[Tong-fei Li](Tong-fei Li)[litongfeihappy@163.com](litongfeihappy@163.com)[ ](litongfeihappy@163.com)Yuanliang Yan  \n[yanyuanliang@csu.edu.cn](yanyuanliang@csu.edu.cn)  \n1Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China  \n2Shiyan Key Laboratory of Natural Medicine Nanoformulation Research, Hubei Key Laboratory of Embryonic Stem Cell Research, School of Basic Medical Sciences, Hubei University of Medicine, Shiyan 442000, Hubei, China  \n3Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China  \n4Clinical Research Center for Breast Cancer in Hunan Province, Changsha 410008, Hunan, China  \n5Department of Radiology, The Second Xiangya Hospital, Central South University, Changsha 410008, Hunan, China  \n6Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA  \n7Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China  \n8National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/. The Creative C","cbCaio8TLIA7XCGi","https://ap.wps.com/l/cbCaio8TLIA7XCGi","pdf",10894459,17,"English","# Abstract\n# Introduction","[{\"question\":\"What is the main strategy developed in this study?\",\"answer\":\"The study develops a nanoplatform that delivers pazopanib (PAZ) using nanometer-sized PAZ@Fe-MOF to improve anti-breast cancer effects.\"},{\"question\":\"How does PAZ@Fe-MOF perform compared with free PAZ?\",\"answer\":\"PAZ@Fe-MOF shows increased anti-tumor therapeutic activity in both syngeneic murine 4T1 and xenograft human MDA-MB-231 breast cancer models.\"},{\"question\":\"How does PAZ@Fe-MOF affect M2-like macrophages in the tumor site?\",\"answer\":\"High-throughput single-cell RNA sequencing indicates that PAZ@Fe-MOF significantly reduces pro-tumorigenic M2-like macrophage populations and suppresses M2-type signaling pathways and chemokines including CCL17, CCL22, and CCL24.\"}]","Determining M2 macrophages content for the anti-tumor effects of metal-organic framework-encapsulated pazopanib nanoparticles in breast cancer | PDF",1790015355,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c560adbc9a4eed74d4fbc9389727314.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/afb236385d78534548bc457705418402.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/210a70cef507ac89d68f7d44ca152895.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ded82fb4357320ced4fb5e0d63739728.webp",980,1306]